Alkem Laboratories Share Price
Sector: Biotechnology & Drugs
4862.00 +10.90 (0.22%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
4824.00
Today’s High
4868.55
52 Week Low
4498.90
52 Week High
6440.00
4841.00 -13.00 (-0.27%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
4824.50
Today’s High
4872.00
52 Week Low
4491.65
52 Week High
6439.90
Key Metrics
- Market Cap (In Cr) 58024.45
- Beta 0.81
- Div. Yield (%) 0.93
- P/B 4.84
- TTM P/E 26.95
- Peg Ratio 2.8
- Sector P/E 22.65
- D/E 0
- Open Price 4854.45
- Prev Close 4851.1
Alkem Laboratories Analysis
Price Analysis
-
1 Week1.02%
-
3 Months-2.98%
-
6 Month-10.22%
-
YTD-13.84%
-
1 Year-4.69%
Risk Meter
- 25% Low risk
- 25% Moderate risk
- 25% Balanced Risk
- 25% High risk
- 25% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 1
- Buy
- 5
- 5
- 5
- 5
- Hold
- 4
- 4
- 5
- 5
- Sell
- 4
- 4
- 3
- 3
- Strong Sell
- 3
- 3
- 3
- 3
- Total
- 17
- 17
- 17
- 17
Alkem Laboratories News
Ola Electric, Mazagon Dock & others to declare Q4 results on May 29
3 min read . 29 May 2025Vinay Rajani of HDFC Sec suggests these 3 stocks to buy in the near-term
3 min read . 24 Apr 2025Why India’s top generics players are rushing to launch this diabetes drug
4 min read . 13 Mar 2025Alkem Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 12964.52
- Selling/ General/ Admin Expenses Total
- 2453.92
- Depreciation/ Amortization
- 357.16
- Other Operating Expenses Total
- 3234.19
- Total Operating Expense
- 10809.53
- Operating Income
- 2154.99
- Net Income Before Taxes
- 2526.41
- Net Income
- 2165.48
- Diluted Normalized EPS
- 181.11
- Period
- 2025
- Total Assets
- 17691.1
- Total Liabilities
- 5706.23
- Total Equity
- 11984.87
- Tangible Book Valueper Share Common Eq
- 957.4
- Period
- 2025
- Cashfrom Operating Activities
- 1912.84
- Cashfrom Investing Activities
- -1298.76
- Cashfrom Financing Activities
- -810.99
- Net Changein Cash
- -186.4
- Period
- 2024
- Total Revenue
- 12667.58
- Selling/ General/ Admin Expenses Total
- 5096.65
- Depreciation/ Amortization
- 299.3
- Other Operating Expenses Total
- 256.98
- Total Operating Expense
- 10681.06
- Operating Income
- 1986.52
- Net Income Before Taxes
- 2023.13
- Net Income
- 1795.77
- Diluted Normalized EPS
- 150.43
- Period
- 2024
- Total Assets
- 15574.9
- Total Liabilities
- 5262.84
- Total Equity
- 10312.06
- Tangible Book Valueper Share Common Eq
- 822.79
- Period
- 2024
- Cashfrom Operating Activities
- 1948.07
- Cashfrom Investing Activities
- -1008.5
- Cashfrom Financing Activities
- -1145.01
- Net Changein Cash
- -207.49
- Period
- 2023
- Total Revenue
- 11599.26
- Selling/ General/ Admin Expenses Total
- 4877.77
- Depreciation/ Amortization
- 310.42
- Other Operating Expenses Total
- 96.33
- Total Operating Expense
- 10320.11
- Operating Income
- 1279.15
- Net Income Before Taxes
- 1304.77
- Net Income
- 984.17
- Diluted Normalized EPS
- 89.9
- Period
- 2023
- Total Assets
- 13756.63
- Total Liabilities
- 4711.34
- Total Equity
- 9045.29
- Tangible Book Valueper Share Common Eq
- 715.32
- Period
- 2023
- Cashfrom Operating Activities
- 1682.5
- Cashfrom Investing Activities
- 112.84
- Cashfrom Financing Activities
- -1760.82
- Net Changein Cash
- 41.62
- Period
- 2022
- Total Revenue
- 10634.19
- Selling/ General/ Admin Expenses Total
- 4240.27
- Depreciation/ Amortization
- 303.96
- Other Operating Expenses Total
- 53.51
- Total Operating Expense
- 8862.68
- Operating Income
- 1771.51
- Net Income Before Taxes
- 1844.28
- Net Income
- 1645.62
- Diluted Normalized EPS
- 137.57
- Period
- 2022
- Total Assets
- 14069.19
- Total Liabilities
- 5431.29
- Total Equity
- 8637.9
- Tangible Book Valueper Share Common Eq
- 682.69
- Period
- 2022
- Cashfrom Operating Activities
- 1111.02
- Cashfrom Investing Activities
- -1435.13
- Cashfrom Financing Activities
- 379.57
- Net Changein Cash
- 57.96
- Period
- 2021
- Total Revenue
- 8865.01
- Selling/ General/ Admin Expenses Total
- 3277.01
- Depreciation/ Amortization
- 274.58
- Other Operating Expenses Total
- 54.83
- Total Operating Expense
- 7195.53
- Operating Income
- 1669.48
- Net Income Before Taxes
- 1842.1
- Net Income
- 1585.02
- Diluted Normalized EPS
- 129.72
- Period
- 2021
- Total Assets
- 11519.26
- Total Liabilities
- 4142.53
- Total Equity
- 7376.73
- Tangible Book Valueper Share Common Eq
- 576.83
- Period
- 2021
- Cashfrom Operating Activities
- 1264.9
- Cashfrom Investing Activities
- -998.54
- Cashfrom Financing Activities
- -271.75
- Net Changein Cash
- -1.72
- Period
- 2020
- Total Revenue
- 8344.36
- Selling/ General/ Admin Expenses Total
- 3310.36
- Depreciation/ Amortization
- 252.76
- Other Operating Expenses Total
- 71.43
- Total Operating Expense
- 7057.36
- Operating Income
- 1287
- Net Income Before Taxes
- 1259.79
- Net Income
- 1127.07
- Diluted Normalized EPS
- 94.42
- Period
- 2020
- Total Assets
- 9945.54
- Total Liabilities
- 3784.87
- Total Equity
- 6160.67
- Tangible Book Valueper Share Common Eq
- 473.7
- Period
- 2020
- Cashfrom Operating Activities
- 585.08
- Cashfrom Investing Activities
- -741.35
- Cashfrom Financing Activities
- 79.15
- Net Changein Cash
- -73.11
- Period
- 2019
- Total Revenue
- 7357.19
- Selling/ General/ Admin Expenses Total
- 3082.65
- Depreciation/ Amortization
- 193.18
- Other Operating Expenses Total
- 58.7
- Total Operating Expense
- 6396.56
- Operating Income
- 960.63
- Net Income Before Taxes
- 954.66
- Net Income
- 760.51
- Diluted Normalized EPS
- 63.98
- Period
- 2019
- Total Assets
- 8208.19
- Total Liabilities
- 2768.85
- Total Equity
- 5439.34
- Tangible Book Valueper Share Common Eq
- 419.4
- Period
- 2019
- Cashfrom Operating Activities
- 779.65
- Cashfrom Investing Activities
- -316.39
- Cashfrom Financing Activities
- -378.94
- Net Changein Cash
- 82.34
- Period
- 2025-03-31
- Total Revenue
- 3143.75
- Selling/ General/ Admin Expenses Total
- 616.35
- Depreciation/ Amortization
- 112.49
- Other Operating Expenses Total
- 856.83
- Total Operating Expense
- 2864.95
- Operating Income
- 278.8
- Net Income Before Taxes
- 395.72
- Net Income
- 305.86
- Diluted Normalized EPS
- 25.57
- Period
- 2025-03-31
- Total Assets
- 17691.1
- Total Liabilities
- 5706.23
- Total Equity
- 11984.87
- Tangible Book Valueper Share Common Eq
- 957.4
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 1912.84
- Cashfrom Investing Activities
- -1298.76
- Cashfrom Financing Activities
- -810.99
- Net Changein Cash
- -186.4
- Period
- 2024-12-31
- Total Revenue
- 3374.28
- Selling/ General/ Admin Expenses Total
- 624.81
- Depreciation/ Amortization
- 85.28
- Other Operating Expenses Total
- 785.75
- Total Operating Expense
- 2700.17
- Operating Income
- 674.11
- Net Income Before Taxes
- 731.07
- Net Income
- 625.82
- Diluted Normalized EPS
- 52.34
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 3414.67
- Selling/ General/ Admin Expenses Total
- 610.49
- Depreciation/ Amortization
- 78.91
- Other Operating Expenses Total
- 846.65
- Total Operating Expense
- 2740.75
- Operating Income
- 673.92
- Net Income Before Taxes
- 780.26
- Net Income
- 688.64
- Diluted Normalized EPS
- 57.6
- Period
- 2024-09-30
- Total Assets
- 17117.03
- Total Liabilities
- 5624.18
- Total Equity
- 11492.85
- Tangible Book Valueper Share Common Eq
- 916.28
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 941.79
- Cashfrom Investing Activities
- -897.83
- Cashfrom Financing Activities
- -321
- Net Changein Cash
- -261.05
- Period
- 2024-06-30
- Total Revenue
- 3031.82
- Selling/ General/ Admin Expenses Total
- 602.27
- Depreciation/ Amortization
- 80.48
- Other Operating Expenses Total
- 744.96
- Total Operating Expense
- 2503.66
- Operating Income
- 528.16
- Net Income Before Taxes
- 619.36
- Net Income
- 545.16
- Diluted Normalized EPS
- 45.6
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 2935.82
- Selling/ General/ Admin Expenses Total
- 505.83
- Depreciation/ Amortization
- 83.43
- Other Operating Expenses Total
- 920.61
- Total Operating Expense
- 2613.63
- Operating Income
- 322.19
- Net Income Before Taxes
- 367.34
- Net Income
- 293.56
- Diluted Normalized EPS
- 24.55
- Period
- 2024-03-31
- Total Assets
- 15574.9
- Total Liabilities
- 5262.84
- Total Equity
- 10312.06
- Tangible Book Valueper Share Common Eq
- 822.79
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1948.07
- Cashfrom Investing Activities
- -1008.5
- Cashfrom Financing Activities
- -1145.01
- Net Changein Cash
- -207.49
- Period
- 2023-12-31
- Total Revenue
- 3323.87
- Selling/ General/ Admin Expenses Total
- 572.15
- Depreciation/ Amortization
- 69.56
- Other Operating Expenses Total
- 739.59
- Total Operating Expense
- 2685.84
- Operating Income
- 638.03
- Net Income Before Taxes
- 654.9
- Net Income
- 594.96
- Diluted Normalized EPS
- 49.76
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Alkem Laboratories Technical
Moving Average
SMA
- 5 Day4785.7
- 10 Day4818.74
- 20 Day4916.97
- 50 Day5033.05
- 100 Day4933.9
- 300 Day5355.99
Alkem Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Lupin
- 1926.1
- -9.1
- -0.47
- 2403.45
- 1545
- 87973.21
- Abbott India
- 33249.95
- 1557.6
- 4.91
- 32229.25
- 25260.2
- 70828.36
- Alkem Laboratories
- 4862
- 10.9
- 0.22
- 6440
- 4498.9
- 58024.45
- Glaxosmithkline Pharmaceutical
- 3277.65
- 14.8
- 0.45
- 3515.95
- 1924.3
- 55387.22
- Glenmark Pharmaceuticals
- 1727.95
- 12.05
- 0.7
- 1830.05
- 1199.95
- 48762.88
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Lupin
- 26.93
- 5.12
- 7.86
- 5.95
- Abbott India
- 47.38
- 15.83
- 32.31
- 18.83
- Alkem Laboratories
- 26.56
- 4.8
- 18.4
- 14.69
- Glaxosmithkline Pharmaceutical
- 59.19
- 28.03
- 29.26
- 16.77
- Glenmark Pharmaceuticals
- 35.81
- 5.37
- 2.17
- 1.82
Alkem Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 29-May-25
- Audited Results & Final Dividend
- 07-Feb-25
- Quarterly Results & Interim Dividend
- 13-Nov-24
- Quarterly Results
- 09-Aug-24
- Quarterly Results
- 29-May-24
- Audited Results & Final Dividend
- 09-Feb-24
- Quarterly Results & Interim Dividend
- 07-Nov-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 19-May-23
- Audited Results & Final Dividend
- 10-Feb-23
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 25-Aug-25
- 29-May-25
- AGM
- 14-Jul-25
- 12-Jun-25
- POM
- 05-Oct-24
- 05-Sept-24
- POM
- 30-Aug-24
- 29-May-24
- AGM
- 09-Apr-24
- 06-Mar-24
- POM
- 08-Jan-24
- 07-Dec-23
- POM
- 09-Oct-23
- 07-Sept-23
- POM
- 25-Aug-22
- 13-May-22
- AGM
- 14-Feb-22
- 11-Jan-22
- POM
- 27-Aug-21
- 25-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 29-May-25
- 08-Aug-25
- -
- 8
- 28-Jan-25
- 14-Feb-25
- 14-Feb-25
- 37
- 29-May-24
- 10-Aug-24
- 09-Aug-24
- 5
- 01-Feb-24
- 17-Feb-24
- 16-Feb-24
- 35
- 19-May-23
- 10-Aug-23
- 10-Aug-23
- 10
- 25-Jan-23
- 18-Feb-23
- 17-Feb-23
- 25
- 24-Jan-23
- 18-Feb-23
- 17-Feb-23
- 15
- 13-May-22
- 10-Aug-22
- 08-Aug-22
- 4
- 24-Jan-22
- 12-Feb-22
- 10-Feb-22
- 30
- 25-May-21
- 10-Aug-21
- 09-Aug-21
- 5


